Figure 1From: Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft modelsAnti-proliferative effects of AZD6244 and BEZ235 in NCI-H1993, NCI-H1975 and NCI-H460 gefitinib-resistant cell lines. Cells were treated with varying concentrations of AZD6244 (A) or BEZ235 (B) alone for 72 h. Doses ranged from 0.01 μM to 100 μM. Mean ± SD, n = 5.Back to article page